A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

Autor Wall, L, Talbot, D C, Bradbury, P, Jodrell, D I
Vydáno 2004

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

Autor Newell, D R, Burtles, S S, Fox, B W, Jodrell, D I, Connors, T A
Vydáno 1999

Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

Autor Jodrell, D. I., Murray, L. S., Reed, N. S., Canney, P. A., Kaye, S. B., Cassidy, J.
Vydáno 1994

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.

Autor Jodrell, D. I., Irvine, A. T., McCready, V. R., Woodcraft, E., Smith, I. E.
Vydáno 1988

Population pharmacokinetics of gentamicin in patients with cancer

Autor Rosario, M C, Thomson, A H, Jodrell*, D I, Sharp, C A, Elliott, H L
Vydáno 1998

Pharmacokinetic studies with the antifolate C2-desamino-C2-methyl-N10-propargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F-NMR spectroscop...

Autor Newell, D. R., Maxwell, R. J., Bisset, G. M., Jodrell, D. I., Griffiths, J. R.
Vydáno 1990

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

Autor Connell, C. M., Raby, S., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., Janowitz, T.
Vydáno v Ann Oncol (2017)

The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.

Autor Jodrell, D. I., Newell, D. R., Morgan, S. E., Clinton, S., Bensted, J. P., Hughes, L. R., Calvert, A. H.
Vydáno 1991

5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

Autor Jodrell, D I, Stewart, M, Aird, R, Knowles, G, Bowman, A, Wall, L, Cummings, J, McLean, C
Vydáno 2001

Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.

Autor Jodrell, D. I., Bowman, A., Stewart, M., Dunlop, N., French, R., MacLellan, A., Cummings, J., Smyth, J. F.
Vydáno 1998

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

Autor Jodrell, D I, Bowman, A, Rye, R, Byrne, B, Boddy, A, Rafi, I, Taylor, G A, Johnston, A, Clendeninn, N J
Vydáno 1999

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

Autor Aird, R E, Cummings, J, Ritchie, A A, Muir, M, Morris, R E, Chen, H, Sadler, P J, Jodrell, D I
Vydáno 2002

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

Autor Jodrell, D. I., Smith, I. E., Mansi, J. L., Pearson, M. C., Walsh, G., Ashley, S., Sinnett, H. D., McKinna, J. A.
Vydáno 1991

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

Autor Lin, Y, Richards, F M, Krippendorff, B-F, Bramhall, J L, Harrington, J A, Bapiro, T E, Robertson, A, Zheleva, D, Jodrell, D I
Vydáno 2012

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

Autor Wong, N A C S, Brett, L, Stewart, M, Leitch, A, Longley, D B, Dunlop, M G, Johnston, P G, Lessells, A M, Jodrell, D I
Vydáno 2001

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

Autor Mackean, M. J., Cassidy, J., Jodrell, D. I., Paul, J., Reed, N. S., Canney, P. A., Yosef, H., Habeshaw, T., Robertson, A. G., McInnes, A., Twelves, C. J.
Vydáno 1998

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

Autor Bapiro, T E, Frese, K K, Courtin, A, Bramhall, J L, Madhu, B, Cook, N, Neesse, A, Griffiths, J R, Tuveson, D A, Jodrell, D I, Richards, F M
Vydáno 2014

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer

Autor Hessmann, E, Patzak, M S, Klein, L, Chen, N, Kari, V, Ramu, I, Bapiro, T E, Frese, K K, Gopinathan, A, Richards, F M, Jodrell, D I, Verbeke, C, Li, X, Heuchel, R, Löhr, J M, Johnsen, S A, Gress, T M, Ellenrieder, V, Neesse, A
Vydáno v Gut (2018)

Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG

Autor Joerger, M, Huitema, A D R, Richel, D J, Dittrich, C, Pavlidis, N, Briasoulis, E, Vermorken, J B, Strocchi, E, Martoni, A, Sorio, R, Sleeboom, H P, Izquierdo, M A, Jodrell, D I, Calvert, A H, Boddy, A, Hollema, H, Féty, R, Van der Vijgh, W J F, Hempel, G, Chatelut, E, Karlsson, M, Tranchand, B, Schrijvers, A H G J, Beijnen, J H, Schellens, J H M
Vydáno 2007

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

Autor Corrie, P. G., Qian, W., Basu, B., Valle, J. W., Falk, S., lwuji, C., Wasan, H., Palmer, D., Scott-Brown, M., Wadsley, J., Arif, S., Bridgewater, J., Propper, D., Gillmore, R., Gopinathan, A., Skells, R., Bundi, P., Brais, R., Dalchau, K., Bax, L., Chhabra, A., Machin, A., Dayim, A., McAdam, K., Cummins, S., Wall, L., Ellis, R., Anthoney, A., Evans, J., Ma, Y. T., Isherwood, C., Neesse, A., Tuveson, D., Jodrell, D. I.
Vydáno v Br J Cancer (2020)